535 studies found for:    Open Studies | "Melanoma"
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Unknown  Dabrafenib Alone and in Combination With Trametinib Before Surgery in Treating Patients With Locally or Regionally Advanced Melanoma That Can Be Removed By Surgery
Conditions: Recurrent Melanoma;   Stage IIB Melanoma (Locally Advanced);   Stage IIC Melanoma (Locally Advanced);   Stage IIIA Melanoma;   Stage IIIB Melanoma;   Stage IIIC Melanoma;   Stage IV Melanoma (Limited, Resectable)
Interventions: Drug: dabrafenib;   Drug: trametinib;   Other: laboratory biomarker analysis
2 Recruiting Study of IDO Inhibitor in Combination With Checkpoint Inhibitors for Adult Patients With Metastatic Melanoma
Conditions: Metastatic Melanoma;   Stage III Melanoma;   Stage IV Melanoma
Interventions: Drug: Indoximod;   Drug: Ipilimumab;   Drug: Nivolumab;   Drug: Pembrolizumab
3 Unknown  Efficacy of Nilotinib in First or Second Line Treatment of Primary Melanomas Stage III Unresectable Melanomas.
Conditions: Malignant Skin Melanoma T0;   Stage III Melanoma;   Stage IV Melanoma;   Amplification
Intervention: Drug: Nilotinib
4 Recruiting RTA 408 Capsules in Patients With Melanoma - REVEAL
Conditions: Melanoma;   Unresectable (Stage III) Melanoma;   Metastatic (Stage IV) Melanoma
Interventions: Drug: Omaveloxolone Capsules (2.5 mg/capsule);   Drug: Ipilimumab (3 mg/kg);   Drug: Nivolumab (3 mg/kg)
5 Recruiting LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations
Conditions: Stage III Melanoma;   Stage IV Melanoma;   Unresectable Melanoma;   BRAF Mutant Melanoma
Intervention: Drug: BRAF inhibitor dabrafenib and MEK inhibitor trametinib
6 Recruiting Identifying Gene Mutations in Patients With Melanoma and in Families With a History of Hereditary Melanoma
Conditions: Hereditary Multiple Melanoma;   Melanoma (Skin)
Interventions: Genetic: gene expression analysis;   Genetic: microarray analysis;   Genetic: molecular genetic technique;   Genetic: mutation analysis;   Other: laboratory biomarker analysis;   Procedure: mutation carrier screening;   Procedure: study of high risk factors
7 Recruiting Pazopanib and Paclitaxel as First-Line Treatment for Subjects With Unresectable Stage III and Stage IV Melanoma
Conditions: Stage III Melanoma;   Stage IV Melanoma;   Unresectable Melanoma
Intervention: Drug: Pazopanib and Paclitaxel
8 Recruiting Phase II Study of Nivolumab in Combination With Ipilimumab for Uveal Melanoma
Conditions: Melanoma;   Uveal Melanoma
Interventions: Drug: Nivolumab;   Drug: Ipilimumab
9 Recruiting Study of the Anti-Angiogenesis Agent Axitinib in Patients With Stage III Malignant Melanoma
Conditions: Melanoma;   Malignant Melanoma
Intervention: Drug: Axitinib
10 Recruiting Neoadjuvant and Adjuvant Checkpoint Blockade in Patients With Clinical Stage III or Oligometastatic Stage IV Melanoma
Conditions: Melanoma;   Oligometastatic Melanoma
Interventions: Drug: Nivolumab 1mg/kg;   Drug: Ipilimumab;   Drug: Nivolumab 3 mg/kg
11 Recruiting Stereotactic Radiation Therapy and Ipilimumab in Treating Patients With Metastatic Melanoma
Conditions: Liver Metastases;   Lung Metastases;   Recurrent Melanoma;   Stage IV Melanoma;   Tumors Metastatic to Brain
Interventions: Biological: ipilimumab;   Radiation: stereotactic radiosurgery;   Other: laboratory biomarker analysis
12 Recruiting Epacadostat and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma
Conditions: Mucosal Melanoma;   Recurrent Melanoma;   Recurrent Uveal Melanoma;   Stage IIIA Skin Melanoma;   Stage IIIA Uveal Melanoma;   Stage IIIB Skin Melanoma;   Stage IIIB Uveal Melanoma;   Stage IIIC Skin Melanoma;   Stage IIIC Uveal Melanoma;   Stage IV Skin Melanoma;   Stage IV Uveal Melanoma
Interventions: Drug: Epacadostat;   Other: Laboratory Biomarker Analysis;   Biological: MELITAC 12.1 Peptide Vaccine
13 Recruiting Adjuvant Sunitinib or Valproic Acid in High-Risk Patients With Uveal Melanoma
Conditions: Ciliary Body and Choroid Melanoma, Medium/Large Size;   Ciliary Body and Choroid Melanoma, Small Size;   Iris Melanoma;   Stage I Intraocular Melanoma;   Stage IIA Intraocular Melanoma;   Stage IIB Intraocular Melanoma;   Stage IIIA Intraocular Melanoma;   Stage IIIB Intraocular Melanoma;   Stage IIIC Intraocular Melanoma
Interventions: Drug: Sunitinib;   Drug: Valproic Acid
14 Not yet recruiting Aldesleukin and Pembrolizumab in Treating Patients With Stage III-IV Melanoma
Conditions: Metastatic Melanoma;   Stage III Mucosal Melanoma of the Head and Neck;   Stage IIIA Skin Melanoma;   Stage IIIB Skin Melanoma;   Stage IIIC Skin Melanoma;   Stage IV Skin Melanoma;   Stage IVA Mucosal Melanoma of the Head and Neck;   Stage IVB Mucosal Melanoma of the Head and Neck;   Stage IVC Mucosal Melanoma of the Head and Neck
Interventions: Biological: Aldesleukin;   Other: Laboratory Biomarker Analysis;   Biological: Pembrolizumab
15 Recruiting A Translational Systems Medicine Approach to Provide Predictive Capacity for Therapy Response in Advanced or Metastatic Malignant Melanoma
Conditions: Advanced Melanoma;   Metastatic Melanoma
Intervention:
16 Recruiting Neoadjuvant Pembrolizumab for Unresectable Stage III and Unresectable Stage IV Melanoma
Conditions: Unresectable Malignant Neoplasm;   Melanoma;   Metastatic Melanoma;   Stage IV Melanoma;   Stage III Melanoma
Intervention: Drug: Pembrolizumab
17 Recruiting High-Dose Aldesleukin and Ipilimumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed By Surgery
Conditions: Recurrent Melanoma;   Stage IIIA Melanoma;   Stage IIIB Melanoma;   Stage IIIC Melanoma;   Stage IV Melanoma
Interventions: Biological: aldesleukin;   Biological: ipilimumab;   Other: laboratory biomarker analysis
18 Recruiting Molecularly Targeted Therapy in Treating Patients With BRAF Wild-type Melanoma That is Metastatic
Conditions: Recurrent Melanoma;   Stage IIIA Melanoma;   Stage IIIB Melanoma;   Stage IIIC Melanoma;   Stage IV Melanoma
Interventions: Other: cytology specimen collection procedure;   Drug: molecularly targeted therapy;   Procedure: therapeutic procedure;   Other: laboratory biomarker analysis;   Procedure: quality-of-life assessment
19 Recruiting High-Dose Recombinant Interferon Alfa-2B, Ipilimumab, or Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery
Conditions: Metastatic Non-Cutaneous Melanoma;   Non-Cutaneous Melanoma;   Recurrent Melanoma of the Skin;   Recurrent Non-Cutaneous Melanoma;   Stage III Mucosal Melanoma of the Head and Neck;   Stage IIIA Skin Melanoma;   Stage IIIB Skin Melanoma;   Stage IIIC Skin Melanoma;   Stage IV Skin Melanoma;   Stage IVA Mucosal Melanoma of the Head and Neck;   Stage IVB Mucosal Melanoma of the Head and Neck;   Stage IVC Mucosal Melanoma of the Head and Neck
Interventions: Biological: Ipilimumab;   Other: Laboratory Biomarker Analysis;   Biological: Pembrolizumab;   Other: Pharmacological Study;   Other: Quality-of-Life Assessment;   Biological: Recombinant Interferon Alfa-2b
20 Recruiting Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery
Conditions: BRAF V600E Mutation Present;   BRAF V600K Mutation Present;   Recurrent Melanoma;   Stage IIIA Skin Melanoma;   Stage IIIB Skin Melanoma;   Stage IIIC Skin Melanoma;   Stage IV Skin Melanoma
Interventions: Drug: Dabrafenib;   Other: Laboratory Biomarker Analysis;   Drug: Trametinib

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years